Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
- Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
- BASF Sells Pharma Business to Abbott
January 1, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
- Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
- Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
- JPMA to Work More Closely with Patients' Organizations
January 1, 2001
- Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
- Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
- Ten More Items to Be Allowed to Be Advertised by Medical Facilities
January 1, 2001
- BUSINESS NEWS IN BRIEF
January 1, 2001
- Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
- Kaletra Included in NHI List
January 1, 2001
- Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
- Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
- NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
- OTC NEWS IN BRIEF
January 1, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…